First Foundation Advisors Regeneron Pharmaceuticals, Inc. Transaction History

First Foundation Advisors

$2.58 Billion
Q3 2024

A detailed history of First Foundation Advisors transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, First Foundation Advisors holds 3,109 shares of REGN stock, worth $2.18 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

3,109

Previous 3,109 -0.0%

Holding current value

$2.18 Million

Previous $3.27 Million 0.03%

% of portfolio

0.13%

Previous 0.13%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$902.69 - $993.35 $45,134 - $49,667	50 Added 1.63%	3,109 $2.99 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $131,005 - $149,007	-169 Reduced 5.24%	3,059 $2.69 Million
Q3 2023 Nov 15, 2023	SELL	$692.45 - $844.37 $692 - $844	-1 Reduced 0.03%	3,228 $2.66 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $96,604 - $114,588	-138 Reduced 4.1%	3,229 $2.32 Million
Q1 2023 May 12, 2023	BUY	$680.49 - $826.97 $44,912 - $54,580	66 Added 2.0%	3,367 $2.77 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $2.33 Million - $2.53 Million	3,301 New	3,301 $2.38 Million
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $1.32 Million - $1.63 Million	-2,422 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$574.03 - $680.96 $216,409 - $256,721	-377 Reduced 13.47%	2,422 $1.47 Million
Q2 2021 Aug 13, 2021	BUY	$472.8 - $558.54 $24,585 - $29,044	52 Added 1.89%	2,799 $1.56 Million
Q1 2021 May 18, 2021	BUY	$446.73 - $548.2 $710,300 - $871,638	1,590 Added 137.42%	2,747 $1.3 Million
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $553,393 - $703,432	1,157 New	1,157 $559,000

Others Institutions Holding REGN

# of Institutions

1,534

Shares Held

83.6M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Foundation Advisors, based on Form 13F filings with the SEC.

News

Stay updated on First Foundation Advisors with notifications on news.

Account

First Foundation Advisors Regeneron Pharmaceuticals, Inc. Transaction History